Novo Nordisk(US:NVO) Prnewswire·2025-03-05 13:00Core Insights - Novo Nordisk is enhancing patient access and affordability for its weight management medication, Wegovy®, with over 55 million people in the U.S. having coverage for such medicines, and 90% of Wegovy® patients with coverage paying between $0 to $25 monthly [1] - The introduction of NovoCare® Pharmacy allows cash-paying patients to receive Wegovy® prescriptions directly at home, fulfilling orders through CenterWell Pharmacy, which has received multiple awards for customer satisfaction [1] - NovoCare® Pharmacy ensures patients receive authentic, FDA-approved Wegovy®, mitigating risks associated with the compounding marketplace, and will soon update savings offers for cash-paying patients using traditional retail pharmacies [1] Company Overview - Novo Nordisk is a leading global healthcare company with over 100 years of experience in developing innovative medicines for diabetes and other chronic diseases, including obesity [14] - The company operates U.S. headquarters in New Jersey and has commercial, production, and research facilities across seven states and Washington D.C., employing approximately 8,000 people [14] Product Information - Wegovy® (semaglutide) is an injectable prescription medicine used alongside a reduced-calorie diet and increased physical activity, specifically for weight management [3] - It is not recommended for use in children under 12 years of age and should not be used with other semaglutide-containing products or GLP-1 receptor agonists [3] Safety and Support - Wegovy® may cause serious side effects, including potential thyroid tumors, pancreatitis, and kidney problems, necessitating careful monitoring and communication with healthcare providers [7][12] - NovoCare® Pharmacy provides additional support services, including benefit verification, refill reminders, and access to live case managers to assist patients [1]